Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  FUJIFILM Holdings Corporation    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan

10/16/2020 | 12:03pm EST
FILE PHOTO: Tablets of Avigan (generic name : Favipiravir), a drug  approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity in Tokyo

TOKYO (Reuters) - Fujifilm Holdings Corp said on Friday it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in Japan, a move that comes after a late-stage study showed reduced recovery time for patients with non-severe symptoms.

Shares of the company closed roughly 3% higher on the news.

The Nikkei newspaper last month cited https://asia.nikkei.com/Spotlight/Coronavirus/Japanese-approval-sought-for-Avigan-to-treat-COVID-19 ministry sources saying approval could be granted to the drug within a month of its application.

Japan has already approved Avigan, known generically as favipiravir, as an emergency flu medicine, which is the subject of at least 16 clinical trials around the world. But concerns remain, as the drug has been shown to cause birth defects in animal studies.

Japan's government has called on Fujifilm to triple national stockpiles of the drug. The company said in a statement it has been working with strategic partners to meet that goal and requests by other countries to supply the drug.

Fujifilm in July signed a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid to sell Avigan for COVID-19 globally, excluding in China, Japan and Russia. The drug has been approved to treat COVID-19 in India and Russia.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.

(Reporting by Chris Gallagher and Sayantani Ghosh; Editing by Stephen Coates, Edwina Gibbs and Shinjini Ganguli)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED 0.96% 5082.1 End-of-day quote.-2.34%
FUJIFILM HOLDINGS CORPORATION -0.48% 6257 End-of-day quote.15.06%
NIKKEI 225 0.67% 28822.29 Real-time Quote.4.33%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.09% 75.2868 Delayed Quote.1.88%
All news about FUJIFILM HOLDINGS CORPORATION
01/06FUJIFILM : says will invest $2 billion in new large-scale cell culture productio..
RE
2020DR REDDY LABORATORIES : . Reddy's Lab's Canadian Unit Seeks Health Canada's Appr..
MT
2020APPILI THERAPEUTICS : Appli Therapeutics Up 3% As Consortium Files Application f..
MT
2020DR REDDY LABORATORIES : . Reddy's Files Application in Canada for COVID-19 Treat..
MT
2020Nikkei hits 3-week low as new virus strain damps recovery hopes
RE
2020Japanese shares drop as new virus strain sparks profit-taking
RE
2020CORRECTION ( : Vietnam-Fujifilm:)
AQ
2020FUJIFILM : Japan's Fujifilm to make coronavirus antigen testing kits in Vietnam
AQ
2020Japan review of Avigan says efficacy for COVID-19 treatment inconclusive -Kyo..
RE
2020SYNTHETICMR : product to be available in Fujifilm's Synapse PACS solution to cus..
AQ
More news
Financials
Sales 2021 2 185 B 21 041 M 21 041 M
Net income 2021 132 B 1 270 M 1 270 M
Net Debt 2021 202 B 1 946 M 1 946 M
P/E ratio 2021 18,9x
Yield 2021 1,53%
Capitalization 2 501 B 24 100 M 24 093 M
EV / Sales 2021 1,24x
EV / Sales 2022 1,15x
Nbr of Employees 73 906
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 6 793,33 JPY
Last Close Price 6 257,00 JPY
Spread / Highest target 59,8%
Spread / Average Target 8,57%
Spread / Lowest Target -15,3%
EPS Revisions
Managers and Directors
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kouichi Tamai Director & Vice President
Takatoshi Ishikawa Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION15.06%24 215
CANON INC.10.82%22 086
BROTHER INDUSTRIES, LTD.9.92%5 851
RICOH COMPANY, LTD.10.78%5 235
KONICA MINOLTA, INC.7.36%2 020
TOSHIBA TEC CORPORATION1.07%1 996